David M. Barrett

Children's Hospital of Philadelphia — United States

Medicine · Health Sciences

59h-index22.0kcitations322works11.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(165), Acute Lymphoblastic Leukemia research(76), Immune Cell Function and Interaction(55), Virus-based gene therapy research(35), Immunotherapy and Immune Responses(29)

Publications321 total

Supplementary Table S1 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Figure S5 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Figure S8 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Figure S4 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Figure S3 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Table S2 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Figure S7 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Figure S6 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Figure S2 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Table S3 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Figure S1 from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Data from D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
2025Open Access
Supplementary Table 2 from Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
2025Open Access
Supplementary Table 1 from Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
2025Open Access
Supplementary Figures from Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
2025Open Access
Supplementary legends from Characterization of Leukemic Resistance to CD19-Targeted CAR T-cell Therapy through Deep Genomic Sequencing
2025Open Access
Placing the cart before the horse: proposals to regulate NHS managers
BMJ Leader·2025Open Access
DDDR-63. Immune remodeling in CSF and tumor predicts response to CAR T therapy in glioblastoma
Neuro-Oncology·2025Open Access
233 Junction adhesion molecule like (JAML) as a novel co-stimulatory molecule for CAR-T cells
Regular and Young Investigator Award Abstracts·2025Open Access
D3-GPC2–Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer
Clinical Cancer Research·2025· 2 citedOpen Access
page 1 of 17Next →

Frequent Co-authors

Stephan A. Grupp(31), David T. Teachey(19), Shannon L. Maude(17), Carl H. June(13), Richard Aplenc(10), Simon F. Lacey(10), Susan R. Rheingold(9), Pamela A. Shaw(8), J. Joseph Melenhorst(8), Bruce L. Levine(8), David L. Porter(7), Colleen Callahan(7), Noelle V. Frey(6), Julie C. Fitzgerald(5), Regina M. Myers(5), Michael L. Blute(4), Stephen P. Hunger(4), Diane Baniewicz(4), Anne Chew(3), Vanessa Gonzalez(3)